tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-14-1-74-82tumors-1288Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISСуществующие проблемы профилактики и лечения химиоиндуцированной периферической нейропатии: мировой опыт и собственные данныеExisting problems of prevention and treatment of chemo-induced peripheral neuropathy: world experience and own datahttps://orcid.org/0000-0002-4979-3246ЧижГ. А.ChizhG.  А.

Чиж Григорий Алексеевич

194017 Санкт-Петербург, пр. Тореза, 72, лит. А;  194100 Санкт-Петербург, ул. Литовская, 2

Chizh Grigorii Alekseevich

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017; 2 Litovskaya str., Saint Petersburg 194100

https://orcid.org/0000-0002-8250-8144РыковИ. В.RykovI.  V.

Рыков Иван Владимирович

194017 Санкт-Петербург, пр. Тореза, 72, лит. А; 197341 СанктПетербург, ул. Аккуратова, 2

Rykov Ivan Vladimirovich

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017; 2 Akkuratova St., Saint Petersburg 197341

rykov.ivan@gmail.comОрловаД. С.OrlovaD.  S.

194017 Санкт-Петербург, пр. Тореза, 72, лит. А 

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017

https://orcid.org/0000-0002-0524-6582КузинС. О.KuzinS.  О.

Кузин Сергей Олегович

194017 Санкт-Петербург, пр. Тореза, 72, лит. А

Kuzin Sergei Olegovich

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017

https://orcid.org/0009-0005-0568-4098ЭльмурзаевА. Б.ElmurzaevА. В.

Эльмурзаев Алим Баширович

194017 Санкт-Петербург, пр. Тореза, 72, лит. А

Elmurzaev Alim Bashirovich

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017

https://orcid.org/0000-0003-3456-6531ШишкинА. Б.ShishkinА. В.

Шишкин Александр Борисович

194017 Санкт-Петербург, пр. Тореза, 72, лит. А

Shishkin Aleksandr Borisovich

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017

БогомоловВ. В.BogomolovV. V.

194017 Санкт-Петербург, пр. Тореза, 72, лит. А

lit. A, 72 Toreza Prospekt, Saint Petersburg 194017

ФГБУЗ «Санкт-Петербургская клиническая больница Российской академии наук»; ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России»РоссияSaint Petersburg Clinical Hospital; Saint Petersburg State Pediatric Medical University, Ministry of Health of RussiaRussian FederationФГБУЗ «Санкт-Петербургская клиническая больница Российской академии наук»; ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииРоссияSaint Petersburg Clinical Hospital; V. A. Almazov National Medical Research Centre, Ministry of Health of RussiaRussian FederationФГБУЗ «Санкт-Петербургская клиническая больница Российской академии наук»РоссияSaint Petersburg Clinical HospitalRussian Federation2024150320241417482Copyright © Чиж Г.А., Рыков И.В., Орлова Д.С., Кузин С.О., Эльмурзаев А.Б., Шишкин А.Б., Богомолов В.В., 20242024Чиж Г.А., Рыков И.В., Орлова Д.С., Кузин С.О., Эльмурзаев А.Б., Шишкин А.Б., Богомолов В.В.Chizh G.А., Rykov I.V., Orlova D.S., Kuzin S.О., Elmurzaev А.В., Shishkin А.В., Bogomolov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1288

Химиоиндуцированная периферическая нейропатия (ХИПН) — осложнение, которое возникает у большинства пациентов при проведении противоопухолевой терапии с применением таксанов и препаратов платины. ХИПН включает в себя широкую палитру клинических проявлений. наиболее частыми из которых выступают нарушения чувствительности. У части пациентов проявления ХИПН сохраняются даже после завершения химиотерапии. Влияние на качество жизни, высокая распространенность ХИПН среди онкологических пациентов, делает актуальным поиск новых методов медикаментозной коррекции данного осложнения. В данном обзоре обсуждаются существующие проблемы в отношении медикаментозной профилактики и лечения ХИПН. Нами также представлен собственный опыт наблюдения за пациентами с химиоиндуцированной нейропатией. Опираясь на результаты наших наблюдений за пациентами, показано влияние данного осложнения на качество жизни пациентов, выходящее за рамки нарушения периферической сенсорной чувствительности. Это следует учитывать при дальнейшем изучении возможности медикаментозной коррекции данного нежелательного явления.

Chemotherapy-related peripheral neuropathy (CIPN) is a complication which occurs in the most cancer patients receiving taxanes and platinum-based systemic therapy. CIPN includes the wide range of clinical symptoms, and the peripheral sensitive disorders are the most common. Some patients have CIPN-related symptoms persistent after chemotherapy completion. Impact on patient's quality of life and high prevalence among cancer patients make an active search for new ways of CIPN medical correction relevant. We reviewed the existing data on medical prophylaxis and treatment of CIPN and also presented our observation data with CIPN patients. Based on our research results, we showed that the impact of CIPN on a patient's quality's life was spread beyond the peripheral sensitivity disorder. This should be taken into account for further studying of the possible correction of CIPN.

химиотерапиянейропатияхимиоиндуцированная периферическая нейропатиятаксаныпрепараты платинылечение нейропатииchemotherapy neuropathychemotherapy-induced peripheral neuropathytaxanesderivatives of platinumneuropathy treatmentReferencesWilliam J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594–608. https://doi.org/10.6004/jnccn.2023.0031William J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594–608. https://doi.org/10.6004/jnccn.2023.0031Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category =1&id =1462NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1462NCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdfNCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdfNCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfNCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfSeretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772–781. https://doi.org/10.1002/ana.24951Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772–781. https://doi.org/10.1002/ana.24951Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33(1):15–49. https://doi.org/10.1053/j.seminoncol.2005.12.010Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33(1):15–49. https://doi.org/10.1053/j.seminoncol.2005.12.010Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16(5):708–16. https://doi.org/10.1634/theoncologist.2010-0248Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16(5):708–16. https://doi.org/10.1634/theoncologist.2010-0248Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312Kalfakis N., Panas M., Karadima G., et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002;59(9):1470–1. https://doi.org/10.1212/01.wnl.0000032505.45389.94Kalfakis N., Panas M., Karadima G., et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002;59(9):1470–1. https://doi.org/10.1212/01.wnl.0000032505.45389.94Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337–40. https://doi.org/10.1212/01.wnl.0000043691.53710.53Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337–40. https://doi.org/10.1212/01.wnl.0000043691.53710.53Chauvenet A.R., Shashi V., Selsky C., et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25(4):316–20. https://doi.org/10.1097/00043426-200304000-00010Chauvenet A.R., Shashi V., Selsky C., et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25(4):316–20. https://doi.org/10.1097/00043426-200304000-00010Gu J., Lu H., Chen C., et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021;29(12):7461–7469. https://doi.org/10.1007/s00520-021-06321-7Gu J., Lu H., Chen C., et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021;29(12):7461–7469. https://doi.org/10.1007/s00520-021-06321-7Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013$19(20):5769–5776. https://doi.org/10.1158/1078-0432.CCR-13-0774McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013$19(20):5769–5776. https://doi.org/10.1158/1078-0432.CCR-13-0774Jennaro T.S., Fang F., Kidwell K.M., et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 2020;180(3):707–714. https://doi.org/10.1007/s10549-020-05584-8Jennaro T.S., Fang F., Kidwell K.M., et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 2020;180(3):707–714. https://doi.org/10.1007/s10549-020-05584-8Hershman D.L., Till C., Wright J.D., et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34(25):3014–22. https://doi.org/10.1200/JCO.2015.66.2346Hershman D.L., Till C., Wright J.D., et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34(25):3014–22. https://doi.org/10.1200/JCO.2015.66.2346Solomon L.R. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer 2016;24(8):3489–94. https://doi.org/10.1007/s00520-016-3175-5Solomon L.R. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer 2016;24(8):3489–94. https://doi.org/10.1007/s00520-016-3175-5EL-Najjar S.E., Naser I.A., AL-Wahidi K.M. Is Functional Vitamin B12 Deficiency a Risk Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients? Research Square 2022. https://doi.org/10.21203/rs.3.rs-1667065/v2EL-Najjar S.E., Naser I.A., AL-Wahidi K.M. Is Functional Vitamin B12 Deficiency a Risk Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients? Research Square 2022. https://doi.org/10.21203/rs.3.rs-1667065/v2Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633–42. https://doi.org/10.1200/JCO.2005.04.0543Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633–42. https://doi.org/10.1200/JCO.2005.04.0543de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47. https://doi.org/10.1200/JCO.2000.18.16.2938de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47. https://doi.org/10.1200/JCO.2000.18.16.2938Park S.B., Goldstein D., Krishnan A.V., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419–37. https://doi.org/10.3322/caac.21204. PMID: 2459086Park S.B., Goldstein D., Krishnan A.V., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419–37. https://doi.org/10.3322/caac.21204.PMID:2459086Loprinzi C.L., Lacchetti C., Bleeker J., et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–3348. https://doi.org/10.1200/JCO.20.01399Loprinzi C.L., Lacchetti C., Bleeker J., et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–3348. https://doi.org/10.1200/JCO.20.01399Jordan B., Margulies A., Cardoso F., et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003Jordan B., Margulies A., Cardoso F., et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003Avallone A., Bimonte S., Cardone C., et al. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res 2022;42(10):4667–4678. https://doi.org/10.21873/anticanres.15971Avallone A., Bimonte S., Cardone C., et al. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res 2022;42(10):4667–4678. https://doi.org/10.21873/anticanres.15971Akin E.J., Alsaloum M., Higerd G.P., et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021;144(6):1727–1737. https://doi.org/10.1093/brain/awab113Akin E.J., Alsaloum M., Higerd G.P., et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021;144(6):1727–1737. https://doi.org/10.1093/brain/awab113Krukowski K., Ma J., Golonzhka O., et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 2017;158(6):1126–1137. https://doi.org/10.1097/j.pain.0000000000000893Krukowski K., Ma J., Golonzhka O., et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 2017;158(6):1126–1137. https://doi.org/10.1097/j.pain.0000000000000893Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. https://doi.org/10.1016/j.expneurol.2011.08.016Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. https://doi.org/10.1016/j.expneurol.2011.08.016Fumagalli G., Monza L., Cavaletti G., et al. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2021:11:626687. https://doi.org/10.3389/fimmu.2020.626687Fumagalli G., Monza L., Cavaletti G., et al. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2021:11:626687. https://doi.org/10.3389/fimmu.2020.626687Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813Farshchian N., Alavi A., Heydarheydari S., et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018;82:787–793. https://doi.org/10.1007/s00280-018-3664-yFarshchian N., Alavi A., Heydarheydari S., et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018;82:787–793. https://doi.org/10.1007/ s00280-018-3664-yMatsuoka H., Clark K., Fazekas B., et al. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open 2022;12(2):e050182. https://doi.org/10.1136/bmjopen-2021-050182Matsuoka H., Clark K., Fazekas B., et al. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open 2022;12(2):e050182. https://doi.org/10.1136/bmjopen-2021-050182Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31(20):2627–33. https://doi.org/10.1200/JCO.2012.44.8738Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31(20):2627–33. https://doi.org/10.1200/JCO.2012.44.8738Kautio A.L., Haanpää M., Saarto T., Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31–9. https://doi.org/10.1016/j.jpainsymman.2007.02.043Kautio A.L., Haanpää M., Saarto T., Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31–9. https://doi.org/10.1016/j.jpainsymman.2007.02.043Gedlicka C., Scheithauer W., Schüll B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359–61. https://doi.org/10.1200/JCO.2002.99.502Gedlicka C., Scheithauer W., Schüll B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359–61. https://doi.org/10.1200/JCO.2002.99.502Guo Y., Jones D., Palmer J.L., et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22(5):1223–31. https://doi.org/10.1007/s00520-013-2075-1Guo Y., Jones D., Palmer J.L., et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22(5):1223–31. https://doi.org/10.1007/ s00520-013-2075-1Dinicola S., Fuso A., Cucina A., et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci 2018;22(14):4739–4754. https://doi.org/10.26355/eurrev_201807_15534.2018Dinicola S., Fuso A., Cucina A., et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci 2018;22(14):4739–4754. https://doi.org/10.26355/eurrev_201807_15534.2018Mitchell P.L., Goldstein D., Michael M., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6(2):146–51. https://doi.org/10.3816/CCC.2006.n.032Mitchell P.L., Goldstein D., Michael M., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6(2):146–51. https://doi.org/10.3816/CCC.2006.n.032

The authors declare that there are no conflicts of interest present.